Long-term treatment study of global standard dose metformin in Japanese patients with type 2 diabetes mellitus
Authors:
- 24 February 2017
- journal article
- research article
- Published by Springer Nature in Diabetology International
- Vol. 8 (3) , 286-295
Abstract
In 169 Japanese patients with type 2 diabetes mellitus with blood glucose levels that were inadequately controlled with diet and exercise therapy alone, or with diet and exercise therapy plus a sulfonylurea (SU) drug, we evaluated the safety and efficacy of global standard dose metformin given up to a maximum daily dose of 2250 mg for 54 weeks. The changes in HbA1c from baseline to the final evaluation visit were −1.32 ± 0.76% for metformin monotherapy and −1.29 ± 0.81% for metformin plus SU, both significantly lower than baseline. The incidences of adverse events and adverse drug reactions were 91.1% (154/169 patients) and 67.5% (114/169 patients), respectively. The most common adverse events were gastrointestinal symptoms, and most of the gastrointestinal symptoms were considered by investigators to be related to metformin treatment. An increased blood lactic acid level was observed in three subjects (1.8%); however, no clinical symptoms were reported, and there was no increase in mean lactic acid concentration throughout the evaluation period. Symptoms of hypoglycemia were reported in 16 patients, all receiving metformin plus SU, but none received metformin monotherapy. There was a decrease in mean body weight. Global standard dose metformin may be useful for maintaining good blood glucose control over the long term in the treatment of type 2 diabetes mellitus in Japanese patients.Keywords
Funding Information
- Dainippon Sumitomo Pharma
This publication has 12 references indexed in Scilit:
- The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of PathogenesisDrug Safety, 2013
- International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program valuesDiabetology International, 2012
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive TherapyNew England Journal of Medicine, 2000
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1995
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993